PolyPid Ltd. (PYPD) Form 6-K — Oct 28, 2026
PolyPid (Nasdaq: PYPD) unveiled an expanded pipeline strategy, introducing PD01B, a new Kynatrix-based product candidate delivering doxycycline directly into wounds to treat moderate-to-severe diabetic foot infections. PD01B will be developed as a new NDA, with an FDA pre-IND meeting and first-in-human study both expected in the second half of 2027. The company hosted a virtual Investor Day featuring podiatric infectious disease expert Warren S. Joseph.
Key figures
- Pdufa date
- 2026-11-28
- Ema decision
- second half 2027
- Us launch target
- early 2027
- Cms ntap decision
- August 2027
- Diabetes adults worldwide
- 589000000
- Pd01b pre IND and first in human
- second half 2027
- One year mortality infected ulcer
- 15%
- One year healing rate infected ulcer
- 46%
- One year amputation rate infected ulcer
- 17%
- Shield ii secondary endpoint relative risk reduction
- 60% (p=0.0013)
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.